Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Onbrez Indacaterol Chronic obstructive pulmonary disease List in a similar manner Complete
Oncaspar pegaspargase Adult Acute Lymphocytic Leukemia (ALL) Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Ondexxya andexanet alfa Reversal of FXa inhibitor anticoagulant effects Do not reimburse Complete
Onglyza Saxagliptin Diabetes mellitus, type 2 Withdrawn
Onglyza Saxagliptin Diabetes mellitus, type 2 List with criteria/condition Complete
Onglyza Saxagliptin Diabetes mellitus (Type 2) Do not list Complete
Onivyde Irinotecan Liposome Metastatic Pancreatic Cancer Reimburse with clinical criteria and/or conditions Complete
Onivyde Nanoliposomal Irinotecan Cancelled
Onpattro patisiran Polyneuropathy in hereditary transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete
Onsolis Fentanyl Citrate Pain, breakthrough cancer pain Do not list Complete